Photobiomodulation Therapy Restores IL-10 Secretion in a Murine Model of Chronic Asthma: Relevance to the Population of CD4+CD25+Foxp3+ Cells in Lung

Frontiers in Immunology

Cristiano Rodrigo de Alvarenga Nascimento¹  Aurileia Aparecida de Brito¹  Renata Kelly da Palma⁴  Karine Zanella Herculano⁵  Cintia Estefano-Alves⁵  Tawany Gonçalves Santos⁵  Nicole Cristine Rigonato-Oliveira⁵  Ana Paula Ligeiro de Oliveira⁵  Maria Cristina Chavantes⁶  Flávio Aimbire⁷ 

[1] Department of Research, Development and Innovation, Innovative Health System Health Management (IHS Medicine and Technology), São Paulo, Brazil;Department of Surgery, School of Veterinary Medicine and Animal Sciences, University of São Paulo, São Paulo, Brazil;Facultad de Ciencias Experimentales, Universidad Francisco de Vitoria, Madrid, Spain;Human Movement and Rehabilitation, Post-Graduate Program Medical School, Evangelic University of Anápolis—UniEVANGELICA, Anápolis, Brazil;Post-Graduate Program in Biophotonics Applied to Health Sciences, University Nove de Julho (UNINOVE), São Paulo, Brazil;Post-Graduate Program in Medicine, University Nove de Julho (UNINOVE), São Paulo, Brazil;Translational Medicine, Federal University of São Paulo—UNIFESP, São José dos Campos, Brazil;

关键词: bronchial asthma;    airway inflammation;    lung mechanics;    Treg cells;    IL-10;    mice;   

DOI  :  10.3389/fimmu.2021.789426

来源: DOAJ

【 摘 要 】

It is largely known that photobiomodulation (PBM) has beneficial effects on allergic pulmonary inflammation. Our previous study showed an anti-inflammatory effect of the PBM in an acute experimental model of asthma, and we see that this mechanism is partly dependent on IL-10. However, it remains unclear whether the activation of regulatory T cells is mediated by PBM in a chronic experimental model of asthma. In this sense, the objective of this study was to verify the anti-inflammatory role of the PBM in the pulmonary inflammatory response in a chronic experimental asthma model. The protocol used for asthma induction was the administration of OVA subcutaneously (days 0 and 14) and intranasally (3 times/week, for 5 weeks). On day 50, the animals were sacrificed for the evaluation of the different parameters. The PBM used was the diode, with a wavelength of 660 nm, a power of 100 mW, and 5 J for 50 s/point, in three different application points. Our results showed that PBM decreases macrophages, neutrophils, and lymphocytes in the bronchoalveolar lavage fluid (BALF). Moreover, PBM decreased the release of cytokines by the lung, mucus, and collagen in the airways and pulmonary mechanics. When we analyzed the percentage of Treg cells in the group irradiated with laser, we verified an increase in these cells, as well as the release of IL-10 in the BALF. Therefore, we conclude that the use of PBM therapy in chronic airway inflammation attenuated the inflammatory process, as well as the pulmonary functional and structural parameters, probably due to an increase in Treg cells.

【 授权许可】

Unknown